Increase of liver stiffness and altered bile acid metabolism after triple CFTR modulator initiation in children and young adults with cystic fibrosis.
ARFI
CFLD
bile acids
cystic fibrosis
Journal
Liver international : official journal of the International Association for the Study of the Liver
ISSN: 1478-3231
Titre abrégé: Liver Int
Pays: United States
ID NLM: 101160857
Informations de publication
Date de publication:
04 2023
04 2023
Historique:
revised:
30
01
2023
received:
09
12
2022
accepted:
14
02
2023
pubmed:
18
2
2023
medline:
22
3
2023
entrez:
17
2
2023
Statut:
ppublish
Résumé
Novel cystic fibrosis transmembrane conductance regulator (CFTR) modulator therapies (elexacaftor/tezacaftor/ivacaftor-ETI) promise clinically significant and sustained improvements for patients with cystic fibrosis (CF). In this study, we investigated the impact of ETI therapy on liver stiffness and bile acid metabolism in a cohort of children and young adults with CF. A prospective observational study (NCT05576324) was conducted from September 2020 to November 2021 enrolling CF patients naive to ETI. Standard laboratory chemistry, sweat test, lung function, share wave velocity (SWV) derived by acoustic radiation force impulse imaging (ARFI) and serum bile acid profiles were assessed before and 6 months after induction of ETI therapy. A total of 20 patients (10 aged <20 years) completed the study. While lung function and BMI improved after ETI therapy, ARFI SWV increased in CF patients <20 years of age (from 1.27 to 1.43 m/s, p = 0.023). Bile acid (BA) profiles revealed a decrease in unconjugated (5.75 vs 1.46, p = 0.007) and increase in glycine-conjugated derivatives (GCDCA) (4.79 vs 6.64 p = 0.016). There was a positive correlation between ARFI SWV values and GCDCA (r = 0.80, p < 0.0001). Glycine-conjugated BA provided high diagnostic accuracy to predict increased ARFI measurements (AUC 0.90) and clinical (Colombo) CFLD grading (AUC 0.97). ARFI SWV and bile acid profiles provide evidence for early increase in liver stiffness and altered bile acid metabolism in young CF patients after initiation of ETI and may serve as synergistic measures for detection of hepatic complications during ETI therapy.
Sections du résumé
BACKGROUND
Novel cystic fibrosis transmembrane conductance regulator (CFTR) modulator therapies (elexacaftor/tezacaftor/ivacaftor-ETI) promise clinically significant and sustained improvements for patients with cystic fibrosis (CF). In this study, we investigated the impact of ETI therapy on liver stiffness and bile acid metabolism in a cohort of children and young adults with CF.
METHODS
A prospective observational study (NCT05576324) was conducted from September 2020 to November 2021 enrolling CF patients naive to ETI. Standard laboratory chemistry, sweat test, lung function, share wave velocity (SWV) derived by acoustic radiation force impulse imaging (ARFI) and serum bile acid profiles were assessed before and 6 months after induction of ETI therapy.
RESULTS
A total of 20 patients (10 aged <20 years) completed the study. While lung function and BMI improved after ETI therapy, ARFI SWV increased in CF patients <20 years of age (from 1.27 to 1.43 m/s, p = 0.023). Bile acid (BA) profiles revealed a decrease in unconjugated (5.75 vs 1.46, p = 0.007) and increase in glycine-conjugated derivatives (GCDCA) (4.79 vs 6.64 p = 0.016). There was a positive correlation between ARFI SWV values and GCDCA (r = 0.80, p < 0.0001). Glycine-conjugated BA provided high diagnostic accuracy to predict increased ARFI measurements (AUC 0.90) and clinical (Colombo) CFLD grading (AUC 0.97).
CONCLUSIONS
ARFI SWV and bile acid profiles provide evidence for early increase in liver stiffness and altered bile acid metabolism in young CF patients after initiation of ETI and may serve as synergistic measures for detection of hepatic complications during ETI therapy.
Substances chimiques
Cystic Fibrosis Transmembrane Conductance Regulator
126880-72-6
CFTR protein, human
0
Banques de données
ClinicalTrials.gov
['NCT05576324']
Types de publication
Observational Study
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
878-887Informations de copyright
© 2023 The Authors. Liver International published by John Wiley & Sons Ltd.
Références
Toledano MB, Mukherjee SK, Howell J, et al. The emerging burden of liver disease in cystic fibrosis patients: a UK nationwide study. PLOS One. 2019;14(4):e0212779.
Colombo C, Battezzati PM, Crosignani A, et al. Liver disease in cystic fibrosis: a prospective study on incidence, risk factors, and outcome. Hepatology. 2002;36(6):1374-1382.
Boëlle PY, Debray D, Guillot L, Clement A, Corvol H, on behalf of the French CF Modifier Gene Study Investigators. Cystic fibrosis liver disease: outcomes and risk factors in a large cohort of French patients. Hepatology. 2019;69(4):1648-1656.
Zolin A, Bossi A, Cirilli N, Kashirskaya N, Padoan R. Cystic fibrosis mortality in childhood. Data from European cystic fibrosis society patient registry. Int J Environ Res Public Health. 2018;15(9):2020.
Middleton PG, Mall MA, Dřevínek P, et al. Elexacaftor-Tezacaftor-Ivacaftor for cystic fibrosis with a single Phe508del allele. N Engl J Med. 2019;381(19):1809-1819.
Heijerman HGM, McKone EF, Downey DG, et al. Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial. Lancet. 2019;394(10212):1940-1948.
Gavioli EM, Guardado N, Haniff F, Deiab N, Vider E. A current review of the safety of cystic fibrosis transmembrane conductance regulator modulators. J Clin Pharm Ther. 2021;46(2):286-294.
Friedrich-Rust M, Schlueter N, Smaczny C, et al. Non-invasive measurement of liver and pancreas fibrosis in patients with cystic fibrosis. J Cyst Fibros. 2013;12(5):431-439.
Karlas T, Neuschulz M, Oltmanns A, et al. Non-invasive evaluation of cystic fibrosis related liver disease in adults with ARFI, transient elastography and different fibrosis scores. PLoS One. 2012;7(7):e42139.
Karlas T, Neuschulz M, Oltmanns A, Wirtz H, Keim V, Wiegand J. ARFI and transient elastography for characterization of cystic fibrosis related liver disease: first longitudinal follow-up data in adult patients. J Cyst Fibros. 2013;12(6):826-827.
Behrens CB, Langholz JH, Eiler J, et al. A pilot study of the characterization of hepatic tissue strain in children with cystic-fibrosis-associated liver disease (CFLD) by acoustic radiation force impulse imaging. Pediatr Radiol. 2013;43(5):552-557.
Fiege J, Mainz JG, Tabori H, Renz DM, Stenzel M, Mentzel HJ. ARFI-Elastographie der Leberbeteiligung bei Zystischer Fibrose. Monatsschr Kinderheilkd. 2017;165(10):888-894.
Kanavaki A, Kanavaki I, Zoumpoulis PS, Moustaki M, Douros K, Loukou I. Changes in share wave elastography after lumacaftor/ivacaftor treatment in children with cystic fibrosis. Curr Drug Saf. 2023;18(1):93-96.
Robb TA, Davidson GP, Kirubakaran C. Conjugated bile acids in serum and secretions in response to cholecystokinin/secretin stimulation in children with cystic fibrosis. Gut. 1985;26(11):1246-1256.
Malhi H, Guicciardi ME, Gores GJ. Hepatocyte death: a clear and present danger. Physiol Rev. 2010;90(3):1165-1194.
Cañas T, Maciá A, Muños-Codoceo RA, et al. Hepatic and splenic acoustic radiation force impulse shear wave velocity Elastography in children with liver disease associated with cystic fibrosis. Biomed Res Int. 2015;2015:517369.
Mentzel H-J, Glutig K, Gräger S, Krüger PC, Waginger M. Ultrasound elastography in children - nice to have for scientific studies or arrived in clinical routine? Molecular and Cellular Pediatrics. 2022;9(1):11.
Friedrich-Rust M, Nierhoff J, Lupsor M, et al. Performance of acoustic radiation force impulse imaging for the staging of liver fibrosis: a pooled meta-analysis. J Viral Hepat. 2012;19(2):e212-e219.
Bota S, Sporea I, Sirli R, Popescu A, Gradinaru-Tașcău O. How useful are ARFI elastography cut-off values proposed by meta-analysis for predicting the significant fibrosis and compensated liver cirrhosis? Med Ultrason. 2015;17(2):200-205.
Kopp BT, McCulloch S, Shrestha CL, et al. Metabolomic responses to lumacaftor/ivacaftor in cystic fibrosis. Pediatr Pulmonol. 2018;53(5):583-591.
Drzymala-Czyz S, Dziedzic K, Szwengiel A, et al. Serum bile acids in cystic fibrosis patients - glycodeoxycholic acid as a potential marker of liver disease. Dig Liver Dis. 2022;54(1):111-117.
Sepe V, Festa C, Renga B, et al. Insights on FXR selective modulation. Speculation on bile acid chemical space in the discovery of potent and selective agonists. Sci Rep. 2016;6:19008.
van de Peppel IP, Doktorova M, Berkers G, et al. IVACAFTOR restores FGF19 regulated bile acid homeostasis in cystic fibrosis patients with an S1251N or a G551D gating mutation. J Cyst Fibros. 2019;18(2):286-293.
Bijvelds MJ, Jorna H, Verkade HJ, et al. Activation of CFTR by ASBT-mediated bile salt absorption. Am J Physiol Gastrointest Liver Physiol. 2005;289(5):G870-G879.
Hernandez GV, Smith VA, Melnyk M, et al. Dysregulated FXR-FGF19 signaling and choline metabolism are associated with gut dysbiosis and hyperplasia in a novel pig model of pediatric NASH. American journal of physiology-gastrointestinal and liver. Phys Ther. 2020;318(3):G582-G609.
Ramsey BW, Davies J, McElvaney N, et al. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. N Engl J Med. 2011;365(18):1663-1672.
Davies JC, Cunningham S, Harris WT, et al. Safety, pharmacokinetics, and pharmacodynamics of ivacaftor in patients aged 2-5 years with cystic fibrosis and a CFTR gating mutation (KIWI): an open-label, single-arm study. Lancet Respir Med. 2016;4(2):107-115.
Keating D, Marigowda G, Burr L, et al. VX-445-Tezacaftor-Ivacaftor in patients with cystic fibrosis and one or two Phe508del alleles. N Engl J Med. 2018;379(17):1612-1620.